Lineage Cell Therapeutics, Inc. (LCTX) Volatility Skew
Implied volatility skew shows how IV varies across strike prices for a given expiration. Steeper skews indicate higher demand for downside protection relative to upside speculation.
Lineage Cell Therapeutics, Inc. (LCTX) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $318.8M, listed on AMEX, employing roughly 70 people, carrying a beta of 1.60 to the broader market. Lineage Cell Therapeutics, Inc. Led by Brian Culley, public since 1992-03-05.
Snapshot as of May 15, 2026.
- Spot Price
- $1.27
- ATM IV
- 174.3%
- IV Skew 25Δ
- 2.720
- IV Rank
- 32.3%
- IV Percentile
- 79.4%
- Term Structure Slope
- -0.313
As of May 15, 2026, Lineage Cell Therapeutics, Inc. (LCTX) at-the-money implied volatility is 174.3%. IV rank is 32.3% (where 0% is the 52-week low and 100% is the 52-week high). IV percentile is 79.4%. The 25-delta skew is +2.720: calls carry premium over puts, indicating upside speculation or squeeze risk. High IV rank typically favors premium-selling strategies; low IV rank favors premium-buying.
LCTX Strategy Selection at Current Volatility Levels
For Lineage Cell Therapeutics, Inc. options at 174.3% ATM IV, mid-range IV rank (32.3%) is the regime where directional conviction matters more than vol-regime positioning; strategy choice should follow the event calendar and the dealer-positioning view rather than IV rank alone. The 25-delta skew tilts to calls, so call-credit spreads or covered-call writes harvest more premium than put-credit spreads of the same width. Pair the vol-rank read with the dealer-gamma view and the upcoming-events calendar to confirm the strategy fits both the structural regime and the path-dependent risk. The variance risk premium - the persistent gap between implied and subsequently realized vol - is positive in equity markets on average; high IV rank typically reflects a stretch where the premium is wider than usual.
Learn how volatility skew is reported and how to read the data →
Frequently asked LCTX volatility skew questions
- What is the current LCTX ATM implied volatility?
- As of May 15, 2026, Lineage Cell Therapeutics, Inc. (LCTX) at-the-money implied volatility is 174.3%. IV rank is 32.3% on a 0-100% scale anchored to the 1-year IV range. ATM IV is the volatility input that makes a Black-Scholes-equivalent model reproduce the listed at-the-money option prices.
- Is LCTX IV high or low historically?
- IV is near its 1-year median, a regime where strategy choice depends on directional conviction and event calendar rather than vol regime.
- What does LCTX volatility skew tell options traders?
- Volatility skew is the pattern by which IV varies across strikes for a given expiration. Lineage Cell Therapeutics, Inc. shows upside-skewed pricing: 25-delta calls trade richer than 25-delta puts, often reflecting upside speculation or squeeze risk. Skew matters for risk-defined strategy selection: when downside puts are rich, put-credit spreads capture more premium; when upside calls are rich, call-credit spreads or covered-call writes harvest more.